Primary Antibodies
Secondary Antibodies
Proteins & Peptides
ELISA Kits
About Us
Contact Us
Antibodies.com Logo Antibodies.com Logo
Sign In/Register
0

Dopaminergic Neuron Markers

Kai Boon Tan, PhD | 4th July 2025

Dopaminergic neurons are specialized neuronal populations that synthesize and release the neurotransmitter dopamine. They play critical roles in motor control,1,2 reward processing,3 cognition,4,5 and neuroendocrine regulation.6,7 Dysfunctions in dopaminergic neurons have been implicated in Parkinson’s disease,8–10 addiction,11 depression,12 schizophrenia,13 attention deficit hyperactivity disorder (ADHD),14,15 and hyperprolactinemia.16,17 Dopaminergic neurons can be found across distinct regions within the central nervous system and classified into nine clusters termed A8–A16.

Dopaminergic neuron markers are proteins that can be used to identify and characterize dopamine-expressing neurons in a mixed population. Below are examples of how dopaminergic neuron markers can be used in basic and translational neuroscience research:

  • Visualize dopaminergic neuron populations in various regions and map their projection, in conjunction with genetic fate-mapping tracer.
  • Apply immunohistochemistry (IHC) in Parkinson’s disease models to assess dopaminergic neuron loss in the substantia nigra or striatal innervation.
  • Characterize the dopaminergic neurons differentiated from patient-derived iPSCs in vitro in regenerative medicine research.
  • Postmortem dopaminergic neuron visualization or quantification to validate neuroimaging (e.g., PET) in the context of psychiatric and neurodegenerative disorders.

Explore allSee Dopaminergic Neuron Marker Antibodies

Table of Contents

Dopaminergic Neuron Marker Summary

Molecular markers Abbreviation Protein Type Description
Tyrosine Hydroxylase TH Enzyme Enzyme in dopamine synthesis. The gold standard for identifying mature dopaminergic neurons across all regions.
Dopa Decarboxylase / Aromatic L-Amino Acid Decarboxylase DDC / AADC Enzyme Enzyme in dopamine synthesis. Co-express with TH in mature dopaminergic neurons.
Dopamine Transporter DAT / SLC6A3 Transporter Reuptakes dopamine from the synaptic cleft. Highly specific to dopaminergic terminals and soma.
Vesicular Monoamine Transporter 2 VMAT2 / SLC18A2 Transporter Packages dopamine into synaptic vesicles.
Aldehyde dehydrogenase 1 family member A1 ALDH1A1 Enzyme Highly enriched in human and primate substantia nigra pars compacta dopaminergic neurons compared to VTA. Less prominent in rodents.
Nuclear receptor related 1 protein NURR1 / NR4A2 Transcription factor Critical transcription factor for the development, maturation, and maintenance of dopaminergic neurons.
Pituitary homeobox PITX3 Transcription factor Essential for the development and survival of substantia nigra pars compacta dopaminergic neurons.
LIM homeobox transcription factor 1 alpha and beta LMX1A/B Transcription factor Key developmental regulator of midbrain dopaminergic neuron specification.
Forkhead box protein A2 FOXA2 Transcription factor Key developmental regulator of midbrain dopaminergic neurons.

Table 1: Summary of common molecular markers used to characterize mature and developing dopaminergic neurons.

Dopaminergic Neuron Functions and Clusters

Dopamine neurons in the brain are primarily distributed across the midbrain and hypothalamus; the pathways of dopaminergic neurotransmission are illustrated in Figure 1.

Diagram of dopaminergic neurotransmission pathways in the human brain

Figure 1: Dopaminergic neurotransmission in the brain. A8-A10 project from the midbrain to the striatum (nigrostriatal pathway), limbic (mesolimbic pathway) regions and cortex (mesocortical pathway), while A11-A15 signal to other cells within the hypothalamus as well as to cells of the pituitary gland (tuberoinfundibular pathway) and spinal cord. A16 is found in the olfactory bulb and projects locally. Hyp: hypothalamus; NAc: nucleus accumbens; OF: olfactory bulb; RRF: retrorubral field; SNc: substantia nigra; VTA: ventral tegmental area.

The midbrain dopaminergic systems comprise the most prominent clusters and include the retrorubral field (RRF) (A8), the substantia nigra pars compacta (SNc) (A9), and the ventral tegmental area (VTA) (A10). The RRF dopaminergic neurons (A8) innervate the ventral striatum and amygdala, contributing to the mesolimbic and mesocortical pathways to modulate reward, motor control, fear, and pain modulation.18,19 The SNc dopaminergic neurons (A9) form the nigrostriatal pathway, projecting to the dorsal striatum to regulate voluntary movement.19,20 Degeneration of this pathway underlies Parkinson's motor symptoms.8–10 The ventral tegmental area (VTA) (A10) dopaminergic neurons project via the mesolimbic and mesocortical pathways to the nucleus accumbens and prefrontal cortex to modulate reward, motivation, and decision-making.19,21

The diencephalon or hypothalamic dopaminergic neuron clusters A11–A15 regulate neuroendocrine, autonomic, and behavioral functions. The posterior hypothalamic dopaminergic group (A11) projects to the spinal cord and modulates spinal autonomic outflow.22 The arcuate nucleus (A12) and periventricular nucleus (A14) neurons innervate the median eminence at the base of the hypothalamus, directly above the pituitary gland, to jointly inhibit prolactin secretion.23,24 The zona incerta (A13) and anteroventral periventricular nucleus (A15) dopaminergic neurons regulate nociception25 and reproductive hormone regulation,26 respectively. Additionally, olfactory bulb dopaminergic neurons (A16) act locally within the olfactory circuit and contribute to olfaction processes such as odor discrimination, olfactory learning, and memory.27,28

Table 2 summarizes key markers found in each cluster of dopaminergic neurons in the mammalian brain.

Dopaminergic Neuron Group Region Primary Target Key Markers
Retrorubral field (RRF) / A8 Midbrain Striatum, amygdala TH+, DAT+, VMAT2+, DDC+, NURR1+, FOXA2+ (low), LMX1A/B+
Substantia nigra pars compacta (SNc) / A9 Midbrain Dorsal striatum TH+, DAT+ (High), VMAT2+, DDC+, PITX3+, ALDH1A1+ (primate-specific), NURR1+, FOXA2+, LMX1A/B+
Ventral tegmental area (VTA) / A10 Midbrain Ventral striatum, prefrontal cortex, limbic system TH+, DAT+ (Moderate), VMAT2+, DDC+, PITX3+, ALDH1A1+ (primate-specific), NURR1+, FOXA2+, LMX1A/B+
Hypothalamic / A11-A15 Hypothalamus Spinal cord, pituitary, hypothalamus TH+, DDC+, DAT- , VMAT2+ (moderate)
Olfactory bulb / A16 Olfactory bulb Periglomerular cells TH+, DDC+, DAT-, VMAT2+ (moderate)
Retinal Retina Amacrine cells TH+, DAT-, VMAT2-

Table 2: Expression of dopaminergic neuron markers in various brain regions

Tyrosine Hydroxylase (TH)

TH is the rate-limiting enzyme in dopamine synthesis (Figure 2). It catalyzes the conversion of L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA), the immediate precursor of dopamine.29 As the first and most critical step in the production of monoamine neurotransmitters, TH is exclusively expressed in dopaminergic,30 noradrenergic,31 and adrenergic neurons.32,33 For dopaminergic neurons, TH serves as the gold-standard pan-dopaminergic marker across the different brain regions, ranging from the midbrain to hypothalamic and olfactory bulb dopaminergic neuron populations.

Diagram of dopamine biosynthesis and clearance at the tripartite synapse

Figure 2: Dopamine synthesis and metabolism in neurons. Dopamine (DA) is synthesized within dopaminergic neurons from tyrosine via L-DOPA by the action of tyrosine hydroxylase (TH) and aromatic amino acid decarboxylase/dopa decarboxylase (AADC / DDC). DA is loaded into vesicles by VMAT2 for synaptic release, with excess DA taken up by neurons for re-use through the dopamine transporter (DAT), or by astrocytes. In neurons or glia, dopamine can be degraded by catechol-o-methyltransferase (COMT) or monoamine oxidase (MAO) to form homovanillic acid (HVA) or be oxidized to form DOPAL and DOPAC metabolites and hydrogen peroxide (H2O2). TH, DDC, VMAT2 and DAT are all common markers of dopaminergic neurons. Reproduced under Creative Commons 4.0 CC-BY from Xu, H., Yang, F. The interplay of dopamine metabolism abnormalities and mitochondrial defects in the pathogenesis of schizophrenia. Transl Psychiatry 12, 464 (2022).

IHC - Anti-Tyrosine Hydroxylase Antibody (A104316)

Figure 3: IHC of rat brain tissue stained with Anti-Tyrosine Hydroxylase Antibody (A104316) in green. Nuclei are marked by DAPI in blue.

IHC - Anti-Tyrosine Hydroxylase Antibody [4H2] (A104315)

Figure 4: IHC of mouse brain tissue stained with Anti-Tyrosine Hydroxylase Antibody [4H2] (A104315).

Dopa Decarboxylase (DDC)

Dopa decarboxylase (DDC), also known as aromatic L-amino acid decarboxylase (AADC), is a pyridoxal phosphate-dependent enzyme responsible for synthesizing key monoamine neurotransmitters.34 DDC is expressed in dopaminergic neurons to catalyze the decarboxylation of L-DOPA to dopamine.35

Clinically, DDC is targeted by peripheral inhibitors like carbidopa to enhance central dopamine delivery in Parkinson’s disease (PD), preventing peripheral L-DOPA degradation.

IHC - Anti-DOPA Decarboxylase/DDC Antibody (A14470)

Figure 5: IHC of rat brain tissue stained with Anti-DOPA Decarboxylase/DDC Antibody (A14470).

DAT

DAT, encoded by the SLC6A3 gene, is a presynaptic membrane transporter that regulates extracellular dopamine levels via sodium-dependent reuptake into dopaminergic neurons.36 DAT terminates dopaminergic signaling by rapidly clearing synaptic dopamine, crucially modulating reward, motivation, and motor control pathways.37 DAT is highly enriched in striatal terminals of SNc (A9) dopaminergic neurons, with relatively lower expression in the VTA (A10) and cortical projections. Clinically, DAT dysfunction is implicated in Parkinson’s disease,38 ADHD,39 and addiction.40

VMAT2

VMAT2, encoded by SLC18A2, is a proton-dependent transporter that packages monoamine neurotransmitters, including dopamine, serotonin, norepinephrine, and histamine, into synaptic vesicles for presynaptic storage and regulated release.41,42 With this, VMAT2 maintains neurotransmitter homeostasis by preventing cytoplasmic dopamine degradation.41 VMAT2 usually localizes to vesicular membranes of dopaminergic neurons and neuroendocrine cells.

ALDH1A1

In dopamine metabolism, ALDH1A1 is a neuroprotective enzyme that catalyzes the oxidation of the highly reactive aldehyde 3,4-dihydroxyphenylacetaldehyde (DOPAL) to 3,4-dihydroxyphenylacetic acid (DOPAC), a benign metabolite that can be excreted from the dopaminergic neuron.43 Without ALDH1A1, DOPAL accumulates in the dopaminergic neurons and leads to α-synuclein aggregation, a hallmark of Parkinson’s disease.44

In translational research, ALDH1A1 is a selective marker for the vulnerable SNc (A9) dopaminergic neuron population that undergoes selective degeneration in Parkinson's disease in humans45 and the non-human primate disease model, where its expression correlates with neuromelanin synthesis and mitochondrial function.46

IF - Anti-ALDH1A1 Antibody (A13666)

Figure 6: IF of HepG2 cells stained with Anti-ALDH1A1 Antibody (A13666).

NURR1

NURR1, encoded by the NR4A2 gene, is an orphan nuclear receptor essential for the development, maintenance, and survival of midbrain dopaminergic neurons. It regulates the expression of key dopaminergic genes, including TH, DAT, and VMAT2, ensuring proper dopamine synthesis, reuptake, and storage.47 During development, NURR1 is critical for the terminal differentiation and maturation of SNc (V9) and VTA (V10) dopaminergic neurons.48 In adulthood, NURR1 continues to protect dopaminergic neurons by maintaining mitochondrial function and reducing oxidative stress.49 Clinically, mutations in the NR4A2 gene are linked to familial forms of Parkinson's disease,50 while pharmacological activation of NURR1 has shown neuroprotective effects in preclinical Parkinson's disease models.51

FOXA2

FOXA2 is a key transcription factor regulating the specification, survival, and functional maintenance of midbrain dopaminergic neurons. FOXA2 is active from early development, cooperating with LMX1A/B and OTX2 to establish midbrain dopaminergic fate in the ventral midbrain floor plate.52 FOXA2 regulates transcription of genes such as TH and DDC for dopamine synthesis, and NURR1 and PITX3 for neuronal survival.53 In adults, FOXA2 continues to protect midbrain dopaminergic neurons by mitigating oxidative stress and sustaining mitochondrial function.54 FOXA2 dysfunction is linked to Parkinson’s disease, where reduced FOXA2 expression correlates with SNc neurodegeneration.55 FOXA2 also guides stem cell-derived DA neuron differentiation, making it a key target for cell replacement therapies.56

Dopaminergic Neuron Marker Antibodies

ALDH1A1 Antibodies
DOPA Decarboxylase Antibodies
Dopamine Transporter Antibodies
FOXA2 Antibodies
Nurr1 Antibodies
Tyrosine Hydroxylase Antibodies
VMAT2 Antibodies

References

  1. Ryczko, D. & Dubuc, R. Dopamine control of downstream motor centers. Curr. Opin. Neurobiol. 83, 102785 (2023).
  2. Bova, A. et al. Precisely timed dopamine signals establish distinct kinematic representations of skilled movements. eLife 9, e61591 (2020).
  3. Bromberg-Martin, E. S., Matsumoto, M. & Hikosaka, O. Dopamine in Motivational Control: Rewarding, Aversive, and Alerting. Neuron 68, 815–834 (2010).
  4. Haubrich, J., Hagena, H., Tsanov, M. & Manahan-Vaughan, D. Editorial: Dopaminergic control of experience encoding, memory and cognition. Front. Behav. Neurosci. 17, (2023).
  5. Millard, S. J. et al. Cognitive representations of intracranial self-stimulation of midbrain dopamine neurons depend on stimulation frequency. Nat. Neurosci. 27, 1253–1259 (2024).
  6. Fontaine, R. et al. Dopaminergic Neurons Controlling Anterior Pituitary Functions: Anatomy and Ontogenesis in Zebrafish. Endocrinology 156, 2934–2948 (2015).
  7. Sourkes, T. L. Neural and neuroendocrine functions of dopamine. Psychoneuroendocrinology 1, 69–78 (1975).
  8. Hegarty, S. V., Sullivan, A. M. & O’Keeffe, G. W. Midbrain dopaminergic neurons: A review of the molecular circuitry that regulates their development. Dev. Biol. 379, 123–138 (2013).
  9. Maiti, P., Manna, J. & Dunbar, G. L. Current understanding of the molecular mechanisms in Parkinson’s disease: Targets for potential treatments. Transl. Neurodegener. 6, 28 (2017).
  10. Kalia, L. V. & Lang, A. E. Parkinson’s disease. The Lancet 386, 896–912 (2015).
  11. Milton, A. L. & Everitt, B. J. The persistence of maladaptive memory: Addiction, drug memories and anti-relapse treatments. Neurosci. Biobehav. Rev. 36, 1119–1139 (2012).
  12. Wang, W. et al. Dorsal raphe dopaminergic neurons target CaMKII+ neurons in dorsal bed nucleus of the stria terminalis for mediating depression-related behaviors. Transl. Psychiatry 14, 408 (2024).
  13. Meyer-Lindenberg, A. et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 5, 267–271 (2002).
  14. MacDonald, H. J., Kleppe, R., Szigetvari, P. D. & Haavik, J. The dopamine hypothesis for ADHD: An evaluation of evidence accumulated from human studies and animal models. Front. Psychiatry 15, (2024).
  15. Véronneau-Veilleux, F., Robaey, P., Ursino, M. & Nekka, F. A mechanistic model of ADHD as resulting from dopamine phasic/tonic imbalance during reinforcement learning. Front. Comput. Neurosci. 16, (2022).
  16. Fitzgerald, P. & Dinan, T. G. Prolactin and dopamine: What is the connection? A Review Article. J. Psychopharmacol. (Oxf.) 22, 12–19 (2008).
  17. Kirsch, P., Kunadia, J., Shah, S. & Agrawal, N. Metabolic effects of prolactin and the role of dopamine agonists: A review. Front. Endocrinol. 13, (2022).
  18. Moaddab, M. & McDannald, M. A. Retrorubral field is a hub for diverse threat and aversive outcome signals. Curr. Biol. 31, 2099-2110.e5 (2021).
  19. Luo, S. X. & Huang, E. J. Dopaminergic Neurons and Brain Reward Pathways. Am. J. Pathol. 186, 478–488 (2016).
  20. Garritsen, O., Van Battum, E. Y., Grossouw, L. M. & Pasterkamp, R. J. Development, wiring and function of dopamine neuron subtypes. Nat. Rev. Neurosci. 24, 134–152 (2023).
  21. Garritsen, O., Van Battum, E. Y., Grossouw, L. M. & Pasterkamp, R. J. Development, wiring and function of dopamine neuron subtypes. Nat. Rev. Neurosci. 24, 134–152 (2023).
  22. Koblinger, K. et al. Characterization of A11 Neurons Projecting to the Spinal Cord of Mice. PLOS ONE 9, e109636 (2014).
  23. Lerant, A., Herman, M. E. & Freeman, M. E. Dopaminergic neurons of periventricular and arcuate nuclei of pseudopregnant rats: semicircadian rhythm in Fos-related antigens immunoreactivities and in dopamine concentration. Endocrinology 137, 3621–3628 (1996).
  24. Lim, L. W. C., Egnot, C. T., Papaioannou, P. & Yip, S. H. The Hypothalamic Arcuate Nucleus Dopaminergic Neurons: More Than Just Prolactin Secretion. Endocrinology 166, bqaf025 (2025).
  25. Moriya, S. et al. Involvement of A13 dopaminergic neurons located in the zona incerta in nociceptive processing: a fiber photometry study. Mol. Brain 13, 60 (2020).
  26. Brown, R. S. E., Herbison, A. E. & Grattan, D. R. Effects of Prolactin and Lactation on A15 Dopamine Neurones in the Rostral Preoptic Area of Female Mice. J. Neuroendocrinol. 27, 708–717 (2015).
  27. Bonzano, S., Bovetti, S., Gendusa, C., Peretto, P. & De Marchis, S. Adult Born Olfactory Bulb Dopaminergic Interneurons: Molecular Determinants and Experience-Dependent Plasticity. Front. Neurosci. 10, (2016).
  28. Capsoni, S., Fogli Iseppe, A., Casciano, F. & Pignatelli, A. Unraveling the Role of Dopaminergic and Calretinin Interneurons in the Olfactory Bulb. Front. Neural Circuits 15, (2021).
  29. Daubner, S. C., Le, T. & Wang, S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys. 508, 1–12 (2011).
  30. Shehadeh, J. et al. Expression of tyrosine hydroxylase isoforms and phosphorylation at serine 40 in the human nigrostriatal system in Parkinson’s disease. Neurobiol. Dis. 130, 104524 (2019).
  31. Pickel, V. M., Joh, T. H. & Reis, D. J. Ultrastructural localization of tyrosine hydroxylase in noradrenergic neurons of brain. Proc. Natl. Acad. Sci. 72, 659–663 (1975).
  32. Bjur, R. A. & Weiner, N. The activity of tyrosine hydroxylase in intact adrenergic neurons of the mouse vas deferens. J. Pharmacol. Exp. Ther. 194, 9–26 (1975).
  33. Weiner, N., Lee, F.-L., Waymire, J. C. & Posiviata, M. The Regulation of Tyrosine Hydroxylase Activity in Adrenergic Nervous Tissue. in Ciba Foundation Symposium 22 - Aromatic Amino Acids in the Brain 135–152 (1974).
  34. Hwu, W.-L., Lee, N.-C., Chien, Y.-H., Muramatsu, S. & Ichinose, H. Chapter Thirteen - AADC Deficiency: Occurring in Humans, Modeled in Rodents. in Advances in Pharmacology (ed. Eiden, L. E.) 68, 273–284 (2013).
  35. Bisello, G. et al. Human aromatic amino acid decarboxylase is an asymmetric and flexible enzyme: Implication in aromatic amino acid decarboxylase deficiency. Protein Sci. 32, e4732 (2023).
  36. Nepal, B., Das, S., Reith, M. E. & Kortagere, S. Overview of the structure and function of the dopamine transporter and its protein interactions. Front. Physiol. 14, (2023).
  37. Dubol, M. et al. Dopamine Transporter and Reward Anticipation in a Dimensional Perspective: A Multimodal Brain Imaging Study. Neuropsychopharmacology 43, 820–827 (2018).
  38. Kägi, G., Bhatia, K. P. & Tolosa, E. The role of DAT-SPECT in movement disorders. J. Neurol. Neurosurg. Amp Psychiatry 81, 5 (2010).
  39. Kuc, K., Bielecki, M., Racicka-Pawlukiewicz, E., Czerwinski, M. B. & Cybulska-Klosowicz, A. The SLC6A3 gene polymorphism is related to the development of attentional functions but not to ADHD. Sci. Rep. 10, 6176 (2020).
  40. Wu, Q., Reith, M. E. A., Kuhar, M. J., Carroll, F. I. & Garris, P. A. Preferential Increases in Nucleus Accumbens Dopamine after Systemic Cocaine Administration Are Caused by Unique Characteristics of Dopamine Neurotransmission. J. Neurosci. 21, 6338 (2001).
  41. Mulvihill, K. G. Presynaptic regulation of dopamine release: Role of the DAT and VMAT2 transporters. Neurochem. Int. 122, 94–105 (2019).
  42. Im, D. et al. Neurotransmitter recognition by human vesicular monoamine transporter 2. Nat. Commun. 15, 7661 (2024).
  43. Kartha, V. K. et al. Functional inference of gene regulation using single-cell multi-omics. Cell Genomics 2, 100166 (2022).
  44. Vlcek, B. et al. Aldh1a1 and additional markers of dopamine cell heterogeneity in substantia nigra and ventral tegmental area identified as preserved in two transgenic α-synuclein mouse models of neurodegenerative disease. Explor. Neuroprotective Ther. 3, 299–327 (2023).
  45. Liu, G. et al. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation. J. Clin. Invest. 124, 3032–3046 (2014).
  46. del Rey, N. L.-G. et al. Calbindin and Girk2/Aldh1a1 define resilient vs vulnerable dopaminergic neurons in a primate Parkinson’s disease model. Npj Park. Dis. 10, 165 (2024).
  47. Zetterström, R. H. et al. Dopamine Neuron Agenesis in Nurr1-Deficient Mice. Science 276, 248–250 (1997).
  48. Saucedo-Cardenas, O. et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl. Acad. Sci. 95, 4013–4018 (1998).
  49. Decressac, M. et al. α-Synuclein–Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons. Sci. Transl. Med. 4, 163ra156-163ra156 (2012).
  50. Le, W. et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33, 85–89 (2003).
  51. Spathis, A. D. et al. Nurr1:RXRα heterodimer activation as monotherapy for Parkinson’s disease. Proc. Natl. Acad. Sci. 114, 3999–4004 (2017).
  52. Ferri, A. L. M. et al. Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner. Development 134, 2761–2769 (2007).
  53. Metzakopian, E. et al. Genome-wide characterization of Foxa2 targets reveals upregulation of floor plate genes and repression of ventrolateral genes in midbrain dopaminergic progenitors. Development 139, 2625–2634 (2012).
  54. Stott, S. R. W. et al. Foxa1 and Foxa2 Are Required for the Maintenance of Dopaminergic Properties in Ventral Midbrain Neurons at Late Embryonic Stages. J. Neurosci. 33, 8022 (2013).
  55. Kittappa, R., Chang, W. W., Awatramani, R. B. & McKay, R. D. G. The foxa2 Gene Controls the Birth and Spontaneous Degeneration of Dopamine Neurons in Old Age. PLOS Biol. 5, e325 (2007).
  56. Arenas, E., Denham, M. & Villaescusa, J. C. How to make a midbrain dopaminergic neuron. Development 142, 1918–1936 (2015).
Show all